Quick answer: in Zepbound vs Mounjaro, the drug is the same: both are tirzepatide, given once weekly at 2.5 mg to 15 mg.[1][2] The difference is the approved use. Mounjaro is approved for type 2 diabetes and to lower heart attack and stroke risk in type 2 diabetes. Zepbound is approved for weight reduction and long-term maintenance and for obstructive sleep apnea in adults with obesity.[1][2] That difference drives which one insurance covers.
For background on how tirzepatide works, see our tirzepatide profile.
Zepbound vs Mounjaro at a glance
| Mounjaro | Zepbound | |
|---|---|---|
| Active drug | Tirzepatide[2] | Tirzepatide[1] |
| First approved | May 2022[5] | November 2023[3] |
| Approved uses | Type 2 diabetes (adults, and children 10+); lowering major cardiovascular events in type 2 diabetes[2] | Weight reduction and long-term maintenance; moderate to severe obstructive sleep apnea with obesity[1] |
| Who it is for | People with type 2 diabetes[2] | Adults with BMI 30+, or 27+ with a weight-related condition; adults with obesity and OSA[1][3] |
| Doses | 2.5 to 15 mg weekly (10 mg max in children)[2] | 2.5 to 15 mg weekly[1] |
| Maintenance dose | Dose that controls blood sugar[2] | 5, 10 or 15 mg (weight); 10 or 15 mg (OSA)[1] |
| Presentations | Single-dose pen and vial, multi-dose vial, KwikPen[2] | Single-dose pen and vial, multi-dose vial, KwikPen[1] |
| Usual coverage route | Diabetes drug benefit | Weight-loss coverage varies; OSA through medical necessity |
Approval history
- Mounjaro, May 2022: approved for blood sugar control in adults with type 2 diabetes.[5]
- Zepbound, November 2023: approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition.[3]
- Zepbound, December 20, 2024: approved for moderate to severe obstructive sleep apnea in adults with obesity, the first drug for this condition.[4] See Zepbound sleep apnea.
- Mounjaro, August 2026: the label added children 10 and older with type 2 diabetes and reduction of cardiovascular death, heart attack and stroke in adults with type 2 diabetes at high risk.[2][5]
Dosing: identical steps, different goals
Both start at 2.5 mg weekly and rise by 2.5 mg no sooner than every 4 weeks, up to 15 mg.[1][2]
- Mounjaro is increased if more blood sugar control is needed.[2]
- Zepbound is increased based on weight response and tolerability, and the label states 2.5 mg is not a maintenance dose.[1]
The missed-dose rules match: take it within 4 days, otherwise skip it.[1][2] See the full tirzepatide dosage chart.
Results: weight loss vs blood sugar
The two brands were tested in different groups of people, so the headline numbers differ.
- Zepbound (SURMOUNT-1), adults without diabetes: 72-week weight loss of 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, versus 3.1% on placebo.[8]
- Mounjaro (SURPASS-1), adults with type 2 diabetes: HbA1c fell 1.87 to 2.07 percentage points at 40 weeks, with weight loss of 7.0 to 9.5 kg.[9]
People with type 2 diabetes generally lose less weight on the same drug. For the full picture, see tirzepatide weight loss results.
Side effects
The side effects are the same type, mainly nausea, diarrhea, vomiting and constipation, mostly during dose increases.[1][2] Reported rates were higher in the Zepbound weight trials. For example, nausea affected 25% to 29% on Zepbound versus 12% to 18% on Mounjaro in their respective placebo-controlled trials.[1][2] Both carry a boxed warning about thyroid C-cell tumors seen in rats.[1][2]
Specific effects are covered in Mounjaro sulfur burps and Mounjaro skin sensitivity.
Pens, vials and self-pay options
Both labels now list four presentations: single-dose pens, single-dose vials, multi-dose vials and a four-dose KwikPen.[1][2]
- Zepbound self-pay: Lilly sells Zepbound single-dose vials and the KwikPen through LillyDirect, starting at $299 a month for the 2.5 mg dose, with the same price for both formats. Lilly announced the KwikPen in February 2026.[6]
- Mounjaro: usually filled through a diabetes prescription and insurance at a retail or mail-order pharmacy.
Prices change often. Check LillyDirect or your plan for current terms.
Insurance and Medicare coverage
The brand name matters most for coverage:
- Mounjaro is usually covered as a diabetes drug when you have a type 2 diabetes diagnosis. Using it for weight loss alone is off-label, and plans commonly require proof of diabetes.[2]
- Zepbound is covered for weight loss only if your plan includes anti-obesity drugs, often with prior authorization. Plans that exclude weight-loss drugs may still cover it for sleep apnea.
- Medicare Part D can cover Mounjaro for type 2 diabetes and Zepbound for moderate to severe sleep apnea.[7]
- Medicare GLP-1 Bridge: since July 1, 2026, eligible Medicare enrollees can get the Zepbound KwikPen for weight management for a $50 monthly copay. The single-dose Zepbound pen and vial are not included, and people with type 2 diabetes or moderate to severe OSA go through their regular Part D plan instead.[7]
Switching between Zepbound and Mounjaro
Because the drug and strengths are identical, moving between the brands is usually a paperwork change, not a dose change.[1][2] Common reasons include a new type 2 diabetes diagnosis, a change of insurance, or a plan that covers one brand but not the other.
A few practical points:
- Keep the same weekly day and the same dose unless your prescriber says otherwise. The missed-dose rules are the same for both brands.[1][2]
- Check the presentation. If you move from a single-dose pen to a vial or KwikPen, the label asks for training on the new device.[1]
- Use only one brand at a time. Taking both would double your tirzepatide dose.[1]
- Expect new paperwork. A new prescription, and often a new prior authorization, is needed.
What users report
Which one is right for you?
The choice usually follows your diagnosis and coverage, not the drug. People with type 2 diabetes are generally prescribed Mounjaro. People without diabetes who need weight management, or who have obesity and moderate to severe sleep apnea, are generally prescribed Zepbound. Your prescriber makes the call. For how tirzepatide compares with semaglutide, see semaglutide vs tirzepatide.
